<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">The Clinician</journal-id><journal-title-group><journal-title xml:lang="en">The Clinician</journal-title><trans-title-group xml:lang="ru"><trans-title>Клиницист</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8338</issn><issn publication-format="electronic">2412-8775</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">307</article-id><article-id pub-id-type="doi">10.17650/1818-8338-2017-11-2-16-23</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEW</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОР</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">PROCALCITONIN TESTING IN RHEUMATOLOGY</article-title><trans-title-group xml:lang="ru"><trans-title>ПРОКАЛЬЦИТОНИНОВЫЙ ТЕСТ В РЕВМАТОЛОГИИ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bukhanova</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Буханова</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>34A Kashirskoe Shosse, Moscow 115522.</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 34А.</p></bio><email>rheumodaria@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Belov</surname><given-names>B. S.</given-names></name><name xml:lang="ru"><surname>Белов</surname><given-names>Б. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>34A Kashirskoe Shosse, Moscow 115522.</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 34А.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tarasova</surname><given-names>G. M.</given-names></name><name xml:lang="ru"><surname>Тарасова</surname><given-names>Г. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>34A Kashirskoe Shosse, Moscow 115522.</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 34А.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dilbaryan</surname><given-names>A. G.</given-names></name><name xml:lang="ru"><surname>Дилбарян</surname><given-names>А. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>34A Kashirskoe Shosse, Moscow 115522.</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 34А.</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">V.A. Nasonova Research Institute of Rheumatology.</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой».</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2017</year></pub-date><volume>11</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>16</fpage><lpage>23</lpage><history><date date-type="received" iso-8601-date="2017-12-18"><day>18</day><month>12</month><year>2017</year></date><date date-type="accepted" iso-8601-date="2017-12-18"><day>18</day><month>12</month><year>2017</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Bukhanova D.V., Belov B.S., Tarasova G.M., Dilbaryan A.G.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, Буханова Д.В., Белов Б.С., Тарасова Г.М., Дилбарян А.Г.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Bukhanova D.V., Belov B.S., Tarasova G.M., Dilbaryan A.G.</copyright-holder><copyright-holder xml:lang="ru">Буханова Д.В., Белов Б.С., Тарасова Г.М., Дилбарян А.Г.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://klinitsist.abvpress.ru/Klin/article/view/307">https://klinitsist.abvpress.ru/Klin/article/view/307</self-uri><abstract xml:lang="en"><p>Currently, differential diagnosis of systemic bacterial infection and active rheumatic process remains a challenging problem in rheumatology. In the review, current data on the role of procalcitonin biomarker in diagnosis and differential diagnosis of rheumatic diseases (RD) and infectious pathology are presented. In particular, some authors recommend procalcitonin (PCT) test as a marker of bacterial infection in bones and joints at levels above 0.5 ng/ml; at PCT level below 0.3 ng/ml, infection can be ruled out. In patients with microcrystalline arthritis, data on the significance of PCT for differential diagnosis are contradictory. PCT level doesn’t correlate with systemic lupus erythematosus activity and is elevated only during bacterial infection proportionally to its systematicity. In some studies, elevated PCT level was observed in ANCA-associated vasculitis with high activity without bacterial infection. It was shown that in 80 % of adults with Still’s disease, PCT level was higher than the threshold value even without infection. For patients with RD hospitalized in intensive care units, PCT clearance is a more informative predictive characteristic than its level, regardless of the cause of PCT elevation (infection, injury, severe organ damage, etc.); slowdown of its decrease is a factor of poor prognosis and is associated with higher mortality. At the same time, PCT level positively correlates with the SOFA score in presence of bacterial infection. For some rheumatic diseases, the threshold PCT value at which the test has optimal sensitivity and specificity is yet to be established. Nonetheless, PCT should be evaluated in relation  to the clinical picture and data of additional examinations. The effect of various therapy methods used in rheumatology on PCT level requires further research.</p></abstract><trans-abstract xml:lang="ru"><p>В ревматологии на сегодняшний день остается актуальным вопрос дифференциальной диагностики системной бактериальной инфекции и активного ревматического процесса. В представленном обзоре приведены современные данные о роли биомаркера прокальцитонина в диагностике и дифференциальной диагностике ревматических заболеваний и инфекционной патологии. В частности, рядом авторов рекомендуется использовать прокальцитониновый тест (ПКТ) как показатель наличия бактериальной инфекции костей и суставов при значениях выше 0,5 нг / мл и исключать инфекцию при значении ПКТ ниже 0,3 нг / мл. При микрокристаллических артритах данные о дифференциально-диагностической значимости ПКТ противоречивы. Уровень ПКТ не коррелирует с активностью системной красной волчанки и повышается только в присутствии бактериальной инфекции пропорционально ее системности. В нескольких работах отмечено повышение уровня ПКТ при АНЦА-ассоциированных васкулитах, протекавших с высокой степенью активности в отсутствие бактериальной инфекции. Показано, что уровень ПКТ у 80 % пациентов с болезнью Стилла взрослых был выше пороговых показателей даже в отсутствие инфекции. Для больных РЗ, находящихся в отделениях интенсивной терапии, клиренс ПКТ является более информативным предиктивным показателем, чем его уровень, вне зависимости от причины повышения ПКТ (инфекция, травма, тяжелое органное поражение и т. п.), замедление его снижения является плохим прогностическим фактором и ассоциируется с повышенной летальностью. При этом уровень ПКТ положительно коррелировал с показателями шкалы SOFA в присутствии бактериальной инфекции. По-прежнему остается спорным вопрос о пороговом значении ПКТ для ряда ревматических заболеваний, при которых этот тест обладал бы наилучшими показателями чувствительности и специфичности. Тем не менее ПКТ всегда следует оценивать в связи с клинической картиной заболевания и данными дополнительных исследований. Необходимо дальнейшее изучение влияния на уровень ПКТ различных методов терапии, применяемых в ревматологии.</p></trans-abstract><kwd-group xml:lang="en"><kwd>procalcitonin</kwd><kwd>procalcitonin testing</kwd><kwd>rheumatic diseases</kwd><kwd>systemic infection</kwd><kwd>septic arthritis</kwd><kwd>systemic lupus erythematosus</kwd><kwd>rheumatic arthritis</kwd><kwd>systemic vasculitis</kwd><kwd>granulomatosis with polyangiitis</kwd><kwd>adult-onset Still’s disease</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>прокальцитонин</kwd><kwd>прокальцитониновый тест</kwd><kwd>ревматические заболевания</kwd><kwd>системная инфекция</kwd><kwd>септический артрит</kwd><kwd>системная красная волчанка</kwd><kwd>ревматоидный артрит</kwd><kwd>системные васкулиты</kwd><kwd>гранулематоз с полиангиитом</kwd><kwd>болезнь Стилла взрослых</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Exarchou S., Lie E., Lindström U. et al. Mortality in ankylosing spondylitis: results from a nationwide population-based study. Ann Rheum Dis 2016;75(8):1466–72. DOI: 10.1136/annrheumdis-2015-207688.</mixed-citation></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Sampaio-Barros P.D., Bortoluzzo A.B., Marangoni R.G. et al. Survival, causes of death, and prognostic factors in systemic sclerosis: analysis of 947 Brazilian patients. J Rheumatol 2012;39(10):1971–8. DOI: 10.3899/jrheum.111582.</mixed-citation><mixed-citation xml:lang="ru">Sampaio-Barros P.D., Bortoluzzo A.B., Marangoni R.G. et al. Survival, causes of death, and prognostic factors in systemic sclerosis: analysis of 947 Brazilian patients. J Rheumatol 2012;39(10):1971–8. DOI: 10.3899/jrheum.111582.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Goldblatt F., Chambers S., Rahman A., Isenberg D.A. Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus 2009;18(8):682–9. DOI: 10.1177/0961203308101019.</mixed-citation><mixed-citation xml:lang="ru">Goldblatt F., Chambers S., Rahman A., Isenberg D.A. Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus 2009;18(8):682–9. DOI: 10.1177/0961203308101019.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Kuo C.F., Luo S.F., See L.C. et al. Rheumatoid arthritis prevalence, incidence, and mortality rates: a nationwide population study in Taiwan. Rheumatol Int 2013;33(2):355–60. DOI: 10.1007/s00296-012-2411-7.</mixed-citation><mixed-citation xml:lang="ru">Kuo C.F., Luo S.F., See L.C. et al. Rheumatoid arthritis prevalence, incidence, and mortality rates: a nationwide population study in Taiwan. Rheumatol Int 2013;33(2):355–60. DOI: 10.1007/s00296-012-2411-7.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><mixed-citation>Lee H. Procalcitonin as a biomarker of infectious diseases. Korean J Intern Med 2013;28(3):285–91. DOI: 10.3904/kjim.2013.28.3.285.</mixed-citation></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Вельков В.В. Прокальцитонин и С-реактивный белок в современной лабораторной диагностике. Часть 1. Клинико-лабораторный консилиум 2008;25(6):46–52. [Vel’kov V.V. Procalcitonin and C-reactive protein in modern laboratory diagnostics. Part 1. Clinical laboratory Council of physicians 2008;25(6):46–52. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Вельков В.В. Прокальцитонин и С-реактивный белок в современной лабораторной диагностике. Часть 1. Клинико-лабораторный консилиум 2008;25(6):46–52. [Vel’kov V.V. Procalcitonin and C-reactive protein in modern laboratory diagnostics. Part 1. Clinical laboratory Council of physicians 2008;25(6):46–52. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Schuetz P., Christ-Crain M., Thomann R. et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009;302(10):1059–66. DOI: 10.1001/jama.2009.1297.</mixed-citation><mixed-citation xml:lang="ru">Schuetz P., Christ-Crain M., Thomann R. et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009;302(10):1059–66. DOI: 10.1001/jama.2009.1297.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Shen C.J., Wu M.S., Lin K.H. et al. The use of procalcitonin in the diagnosis of bone and joint infection: a systemic review and meta-analysis. Eur J Clin Microbiol Infect Dis 2013;32(6):807–14. DOI: 10.1007/s10096-012-1812-6.</mixed-citation><mixed-citation xml:lang="ru">Shen C.J., Wu M.S., Lin K.H. et al. The use of procalcitonin in the diagnosis of bone and joint infection: a systemic review and meta-analysis. Eur J Clin Microbiol Infect Dis 2013;32(6):807–14. DOI: 10.1007/s10096-012-1812-6.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Liu W., Sigdel K.R., Wang Y. et al. High Level Serum Procalcitonin Associated Gouty Arthritis Susceptibility: From a Southern Chinese Han Population. PLoS ONE 2015;10(7):e0132855. DOI: 10.1371/journal.pone.0132855.</mixed-citation><mixed-citation xml:lang="ru">Liu W., Sigdel K.R., Wang Y. et al. High Level Serum Procalcitonin Associated Gouty Arthritis Susceptibility: From a Southern Chinese Han Population. PLoS ONE 2015;10(7):e0132855. DOI: 10.1371/journal.pone.0132855.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><mixed-citation>Choi S.T., Song J.S. Serum Procalcitonin as a Useful Serologic Marker for Differential Diagnosis between Acute Gouty Attack and Bacterial Infection. Yonsei Med J 2016;57(5):1139–44. DOI: 10.3349/ymj.2016.57.5.1139.</mixed-citation></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Wang C., Zhong D., Liao Q. et al. Procalcitonin levels in fresh serum and fresh synovial fluid for the differential diagnosis of knee septic arthritis from rheumatoid arthritis, osteoarthritis and gouty arthritis. Exp Ther Med 2014;8(4):1075–80. DOI: 10.3892/etm.2014.1870. PMID: 25187799.</mixed-citation><mixed-citation xml:lang="ru">Wang C., Zhong D., Liao Q. et al. Procalcitonin levels in fresh serum and fresh synovial fluid for the differential diagnosis of knee septic arthritis from rheumatoid arthritis, osteoarthritis and gouty arthritis. Exp Ther Med 2014;8(4):1075–80. DOI: 10.3892/etm.2014.1870. PMID: 25187799.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Martinot M., Sordet C., Soubrier M. et al. Diagnostic value of serum and synovial procalcitonin in acute arthritis: a prospective study of 42 patients. Clin Exp Rheumatol 2005;23(3):303–31. PMID: 15971417.</mixed-citation><mixed-citation xml:lang="ru">Martinot M., Sordet C., Soubrier M. et al. Diagnostic value of serum and synovial procalcitonin in acute arthritis: a prospective study of 42 patients. Clin Exp Rheumatol 2005;23(3):303–31. PMID: 15971417.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><mixed-citation>Streit G., Alber D., Toubin M.M. et al. Procalcitonin, C-reactive protein, and complement-3a assays insynovial fluid for diagnosing septic arthritis: preliminary results. Joint Bone Spine 2008;75(2):238–9. DOI: 10.1016/j.jbspin.2007.07.012.</mixed-citation></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Spahr L., Morard I., Hadengue A. et al. Procalcitonin is not an accurate marker of spontaneous bacterial peritonitis in patients with cirrhosis. Hepatogastroenterology 2001;48(38):502–5. PMID: 11379342.</mixed-citation><mixed-citation xml:lang="ru">Spahr L., Morard I., Hadengue A. et al. Procalcitonin is not an accurate marker of spontaneous bacterial peritonitis in patients with cirrhosis. Hepatogastroenterology 2001;48(38):502–5. PMID: 11379342.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Viallon A., Desseigne N., Marjollet O. et al. Meningitis in adult patients with a negative direct cerebrospinal fluid examination: value of cytochemical markers for differential diagnosis. Crit Care 2011;15(3):R136. DOI: 10.1186/cc10254.</mixed-citation><mixed-citation xml:lang="ru">Viallon A., Desseigne N., Marjollet O. et al. Meningitis in adult patients with a negative direct cerebrospinal fluid examination: value of cytochemical markers for differential diagnosis. Crit Care 2011;15(3):R136. DOI: 10.1186/cc10254.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Volante E., Moretti S., Pisani F., Bevilacqua G. Early diagnosis of bacterial infection in the neonate. J Matern Fetal Neonatal Med 2004;16 Suppl 2:13–6. DOI: 10.1080/14767050410001727116. PMID: 15590427.</mixed-citation><mixed-citation xml:lang="ru">Volante E., Moretti S., Pisani F., Bevilacqua G. Early diagnosis of bacterial infection in the neonate. J Matern Fetal Neonatal Med 2004;16 Suppl 2:13–6. DOI: 10.1080/14767050410001727116. PMID: 15590427.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Wu J.Y., Lee S.H., Shen C.J. et al. Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and metaanalysis. Arthritis Rheum 2012;64(9):3034–42. DOI: 10.1002/art.34512.</mixed-citation><mixed-citation xml:lang="ru">Wu J.Y., Lee S.H., Shen C.J. et al. Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and metaanalysis. Arthritis Rheum 2012;64(9):3034–42. DOI: 10.1002/art.34512.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><mixed-citation>Scire C.A., Cavagna L., Perotti C. et al. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol 2006;24(2):123–8. PMID: 16762145.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Лапин С.В., Маслянский А.Л., Лазарева Н.М. и др. Значение количественного определения прокальцитонина для диагностики септических осложнений у больных с аутоиммунными ревматическими заболеваниями Клиническая лабораторная диагностика 2013;(1):28–33. [Lapin S.V., Maslyan- skiy A.L., Lazareva N.M. et al. The value of quantitative determination of procalcitonin for the diagnosis of septic complications in patients with autoimmune rheumatic diseases. Klinicheskaya laboratornaya diagnostika = Clinical Laboratory Diagnostics 2013;(1):28–33. (In Russ.)].</mixed-citation></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Тарасова Г .М., Белов Б.С., Александрова Е.Н., Новиков А.А. Прокальцитониновый тест при ревматических заболеваниях. Научно-практическая ревматология 2014;52(4):387–92. [Tarasova G.M., Belov B.S., Aleksandrova E.N., Novikov A.A. Procalcitonin test in rheumatic diseases. Nauchno-prakticheskaya revmatologiya = ScientificPractical Rheumatology 2014;52(4): 387–92. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Тарасова Г .М., Белов Б.С., Александрова Е.Н., Новиков А.А. Прокальцитониновый тест при ревматических заболеваниях. Научно-практическая ревматология 2014;52(4):387–92. [Tarasova G.M., Belov B.S., Aleksandrova E.N., Novikov A.A. Procalcitonin test in rheumatic diseases. Nauchno-prakticheskaya revmatologiya = ScientificPractical Rheumatology 2014;52(4): 387–92. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><mixed-citation>Ho W-L., Lan J-L., Chen D-Y. et al. Procalcitonin may be a potential biomarker for distinguishing bacterial infection from disease activity in febrile patients with systemic lupus erythematosus. Formosan J Rheumatol 2009;23:52–8. DOI: 10.1007/s10067-015-3020-0.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Shin K.C., Lee Y.J., Kang S.W. et al. Serum procalcitonin measurement for detection of intercurrent infection in febrile patients with SLE. Ann Rheum Dis 2001;60(10):988–9. PMID: 11589181.</mixed-citation></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Quintana G., Medina Y., Rojas C. et al. The use of procalcitonin determinations in evaluation of systemic lupus erythematosus. J Clin Rheum 2008;14(3):138–42. DOI: 10.1097/RHU.0b013e3181772cca.</mixed-citation><mixed-citation xml:lang="ru">Quintana G., Medina Y., Rojas C. et al. The use of procalcitonin determinations in evaluation of systemic lupus erythematosus. J Clin Rheum 2008;14(3):138–42. DOI: 10.1097/RHU.0b013e3181772cca.</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Schwenger V., Sis J., Breitbart A. et al. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection 1998;26(5):274–6. PMID: 9795783.</mixed-citation><mixed-citation xml:lang="ru">Schwenger V., Sis J., Breitbart A. et al. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection 1998;26(5):274–6. PMID: 9795783.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Yu J., Xu B., Huang Y., et al. Serum procalcitonin and C-reactive protein for differentiating bacterial infection from disease activity in patients with systemic lupus erythematosus. Mod Rheumatol 2014;24(3):457–63. DOI: 10.3109/14397595.2013.844391.</mixed-citation><mixed-citation xml:lang="ru">Yu J., Xu B., Huang Y., et al. Serum procalcitonin and C-reactive protein for differentiating bacterial infection from disease activity in patients with systemic lupus erythematosus. Mod Rheumatol 2014;24(3):457–63. DOI: 10.3109/14397595.2013.844391.</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Bador K.M., Intan S., Hussin S., Gafor A.H. Serum procalcitonin has negative predictive value for bacterial infection in active systemic lupus erythematosus. Lupus 2012;21(11):1172–7. DOI: 10.1177/0961203312450085.</mixed-citation><mixed-citation xml:lang="ru">Bador K.M., Intan S., Hussin S., Gafor A.H. Serum procalcitonin has negative predictive value for bacterial infection in active systemic lupus erythematosus. Lupus 2012;21(11):1172–7. DOI: 10.1177/0961203312450085.</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Lanoix J.P., Bourgeois A.M., Schmidt J. et al. Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus. Lupus 2011;20(2):125–30. DOI: 10.1177/0961203310378862.</mixed-citation><mixed-citation xml:lang="ru">Lanoix J.P., Bourgeois A.M., Schmidt J. et al. Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus. Lupus 2011;20(2):125–30. DOI: 10.1177/0961203310378862.</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Wallbach M., Vasko R., Hoffmann S. et al. Elevated procalcitonin levels in a severe lupus flare without infection. Lupus 2016;25(14):1625–6. DOI: 10.1177/0961203316651746. PMID: 27216419.</mixed-citation><mixed-citation xml:lang="ru">Wallbach M., Vasko R., Hoffmann S. et al. Elevated procalcitonin levels in a severe lupus flare without infection. Lupus 2016;25(14):1625–6. DOI: 10.1177/0961203316651746. PMID: 27216419.</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><mixed-citation>Eberhard O.K., Haubitz M., Brunkhorst F.M. et al. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibodyassociated vasculitis) and invasive bacterial infection. Arthritis Rheum 1997;40(7):1250–6. DOI: 10.1002/1529-0131(199707)40: 7&lt;1250::AID-ART9&gt;3.0.CO;2-A. PMID: 9214425.</mixed-citation></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Lu X.L., Xiao Z.H., Yang M.Y., Zhu Y.M. Diagnostic value of serum procalcitonin in patients with chronic renal insufficiency: a systematic review and meta-analysis. Nephrol Dial Transplant 2012;28(1): 122–9. DOI: 10.1093/ndt/gfs339.</mixed-citation><mixed-citation xml:lang="ru">Lu X.L., Xiao Z.H., Yang M.Y., Zhu Y.M. Diagnostic value of serum procalcitonin in patients with chronic renal insufficiency: a systematic review and meta-analysis. Nephrol Dial Transplant 2012;28(1): 122–9. DOI: 10.1093/ndt/gfs339.</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><mixed-citation>Dumea R., Siriopol D., Hogas S. et al. Procalcitonin: diagnostic value in systemic infections in chronic kidney disease or renal transplant patients. Int Urol Nephrol 2013;46(2):461–8. DOI: 10.1007/s11255013-0542-8.</mixed-citation></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Serio I., Arnaud L., Mathian A. et al. Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review. Clin Rheumatol 2014;33(9):1209–15. DOI: 10.1007/s10067-014-2738-4.</mixed-citation><mixed-citation xml:lang="ru">Serio I., Arnaud L., Mathian A. et al. Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review. Clin Rheumatol 2014;33(9):1209–15. DOI: 10.1007/s10067-014-2738-4.</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">Zycinska K., Wardyn K.A., Zielonka T.M. et al. Procalcitonin as an indicator of systemic response to infection in active pulmonary Wegener’s granulomacytosis. J Physiol Pharmacol 2008;59(Suppl 6): 839–44. PMID: 19218712.</mixed-citation><mixed-citation xml:lang="ru">Zycinska K., Wardyn K.A., Zielonka T.M. et al. Procalcitonin as an indicator of systemic response to infection in active pulmonary Wegener’s granulomacytosis. J Physiol Pharmacol 2008;59(Suppl 6): 839–44. PMID: 19218712.</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><mixed-citation>Moosig F., Csernok E., Reinhold-Keller E. et al. Elevated procalcitonin levels in active Wegener’s Granulomatosis. J Rheumatol 1998;25(8):1531–3. PMID: 9712096.</mixed-citation></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">Delevaux I., Andre M., Colombier M. et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis 2003;62(4): 337–40. PMID: 12634233.</mixed-citation><mixed-citation xml:lang="ru">Delevaux I., Andre M., Colombier M. et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis 2003;62(4): 337–40. PMID: 12634233.</mixed-citation></citation-alternatives></ref><ref id="B36"><label>36.</label><citation-alternatives><mixed-citation xml:lang="en">Tombetti E., DI Chio M.C., Sartorelli S. et al. Procalcitonin in takayasu arteritis. J Rheumatol 2014;41(7):1564–6. DOI: 10.3899/jrheum.131340.</mixed-citation><mixed-citation xml:lang="ru">Tombetti E., DI Chio M.C., Sartorelli S. et al. Procalcitonin in takayasu arteritis. J Rheumatol 2014;41(7):1564–6. DOI: 10.3899/jrheum.131340.</mixed-citation></citation-alternatives></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">Morath C., Sis J., Haensch G.M. et al. Procalcitonin as marker of infection in patients with Goodpasture’s syndrome is misleading. Nephrol Dial Transplant 2007;22(9):2701–4. DOI: 10.1093/ndt/gfm353. PMID: 17556410.</mixed-citation><mixed-citation xml:lang="ru">Morath C., Sis J., Haensch G.M. et al. Procalcitonin as marker of infection in patients with Goodpasture’s syndrome is misleading. Nephrol Dial Transplant 2007;22(9):2701–4. DOI: 10.1093/ndt/gfm353. PMID: 17556410.</mixed-citation></citation-alternatives></ref><ref id="B38"><label>38.</label><mixed-citation>Sato H., Tanabe N., Murasawa A. et al. Procalcitonin is a specific marker for detecting bacterial infection in patients with rheumatoid arthritis. J Rheumatol 2012;39(8):1517–23. DOI: 10.3899/jrheum.111601.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Tsujimoto K., Hata A., Fujita M. et al. Presepsin and procalcitonin as biomarkers of systemic bacterial infection in patients with rheumatoid arthritis. Int J Rheum Dis 2016 Jun 13. DOI: 10.1111/1756185X.12899. [Epub ahead of print]</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Ozmen M., Oktay E., Tarhan E.F. et al. Serum procalcitonin levels in patients with ankylosing spondylitis. Int J Rheum Dis 2016;19(5):500–5. DOI: 10.1111/1756185X.12386.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Chen D.Y., Chen Y.M., Ho W.L. et al. Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infectious inflammation in febrile patients with active adult-onset Still’s disease. Ann Rheum Dis 2009;68(6):1074–5. DOI: 10.1136/ard.2008.098335.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Buhaescu I., Yood R.A., Izzedine H. Serum procalcitonin in systemic autoimmune diseases – where are we now? Semin Arthritis Rheum 2010;40(2):176–83. DOI: 10.1016/j.semarthrit.2009.10.004.</mixed-citation></ref><ref id="B43"><label>43.</label><citation-alternatives><mixed-citation xml:lang="en">Tamaki K., Kogata Y., Sugiyama D. et al. Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases. J Rheumatol 2008;35(1):114–9. PMID: 18050369.</mixed-citation><mixed-citation xml:lang="ru">Tamaki K., Kogata Y., Sugiyama D. et al. Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases. J Rheumatol 2008;35(1):114–9. PMID: 18050369.</mixed-citation></citation-alternatives></ref><ref id="B44"><label>44.</label><citation-alternatives><mixed-citation xml:lang="en">Perren A., Cerutti B., Lepori M. et al. Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia. Infection 2008;36(2):163–6. DOI: 10.1007/s15010-007-7206-5.</mixed-citation><mixed-citation xml:lang="ru">Perren A., Cerutti B., Lepori M. et al. Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia. Infection 2008;36(2):163–6. DOI: 10.1007/s15010-007-7206-5.</mixed-citation></citation-alternatives></ref><ref id="B45"><label>45.</label><citation-alternatives><mixed-citation xml:lang="en">de Kruif M.D., Lemaire L.C., Giebe- len I.A. et al. The influence of corticosteroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med 2008;34(3):518–22. DOI: 10.1007/s00134-007-0955-x. PMID: 18080111.</mixed-citation><mixed-citation xml:lang="ru">de Kruif M.D., Lemaire L.C., Giebe- len I.A. et al. The influence of corticosteroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med 2008;34(3):518–22. DOI: 10.1007/s00134-007-0955-x. PMID: 18080111.</mixed-citation></citation-alternatives></ref><ref id="B46"><label>46.</label><citation-alternatives><mixed-citation xml:lang="en">Rinaldi S., Adembri C., Grechi S., De Gaudio A.R. Low-dose hydrocortisone during severe sepsis: effects on microalbuminuria. Crit Care Med 2006;34(9): 2334–9. DOI: 10.1097/01.CCM.0000233872.04706.BB. PMID: 16850006.</mixed-citation><mixed-citation xml:lang="ru">Rinaldi S., Adembri C., Grechi S., De Gaudio A.R. Low-dose hydrocortisone during severe sepsis: effects on microalbuminuria. Crit Care Med 2006;34(9): 2334–9. DOI: 10.1097/01.CCM.0000233872.04706.BB. PMID: 16850006.</mixed-citation></citation-alternatives></ref><ref id="B47"><label>47.</label><citation-alternatives><mixed-citation xml:lang="en">Lin C.H., Hsieh S.C., Keng L.T. et al. Prospective Evaluation of Procalcitonin, Soluble Triggering Receptor Expressed on Myeloid Cells-1 and CReactive Protein in Febrile Patients with Autoimmune Diseases. PLoS ONE 2016;11(4): e0153938. DOI: 10.1371/journal. pone.0153938.</mixed-citation><mixed-citation xml:lang="ru">Lin C.H., Hsieh S.C., Keng L.T. et al. Prospective Evaluation of Procalcitonin, Soluble Triggering Receptor Expressed on Myeloid Cells-1 and CReactive Protein in Febrile Patients with Autoimmune Diseases. PLoS ONE 2016;11(4): e0153938. DOI: 10.1371/journal. pone.0153938.</mixed-citation></citation-alternatives></ref><ref id="B48"><label>48.</label><citation-alternatives><mixed-citation xml:lang="en">Sitter J.T., Schmidt M., Schneider S., Schiffl H. Differential diagnosis of bacterial infection and inflammatory response in kidney diseases using procalcitonin. J Nephrol 2002;15(3):297–301. PMID: 12113602.</mixed-citation><mixed-citation xml:lang="ru">Sitter J.T., Schmidt M., Schneider S., Schiffl H. Differential diagnosis of bacterial infection and inflammatory response in kidney diseases using procalcitonin. J Nephrol 2002;15(3):297–301. PMID: 12113602.</mixed-citation></citation-alternatives></ref><ref id="B49"><label>49.</label><mixed-citation>Shi Y., Peng J.M., Hu X., Wang Y. The utility of initial procalcitonin and procalcitonin clearance for prediction of bacterial infection and outcome in critically ill patients with autoimmune diseases: a prospective observational study. BMC Аnesthesiol 2015;15:137. DOI: 10.1186/s12862-015-0424-z.</mixed-citation></ref></ref-list></back></article>
